Masseter muscle thickness is predictive of cancer cachexia in patients with head and neck cancer
Related Experiment Video
Updated: Jun 27, 2025
Rodent Model of Masseter Volumetric Muscle Loss for Studying Bioengineering Materials
Published on: May 31, 2024
Julián Balanta-Melo1,2, Alexander J Jones3, Leah J Novinger4,5
1Department of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Background:
Cancer cachexia is prevalent in head and neck cancer patients. The L3 skeletal muscle index (SMI) is often used to assess sarcopenia and cachexia but is infrequently able to be measured in this population. Masseter muscle thickness (MT) may serve as an alternative predictor of cachexia.
Methods:
SMI and MT were calculated from 20 trauma (CTRL) and 40 cachectic (CA-CX) and non-cachectic (CA-NCX) head and neck cancer patients. Area Under the Curve of the Receiver Operating Characteristics (AUC-ROC) analysis was performed for SMI and MT.
Results:
Both SMI and MT were significantly decreased in CA-CX patients (vs. CA-NCX mean difference -19.5 cm2/m2 and -2.06 mm, respectively) and significant predictors of CA-CX (AUC = 0.985 and 0.805, respectively). When analyzed by sex, the same findings were observed for MT in males and trended toward significance in females.
Conclusions:
Compared with SMI, MT is a good alternative prognostic biomarker to determine CA-CX status in HNC patients.
